In a Key Win for Parse, Patent Trial and Appeal Board Invalidates 10x Genomics Patent Claims
Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman
10x Genomics Announces Its Chromium Single Cell Gene Expression And Xenium In Situ Platforms Were Used In A Publication, Featured On The Cover Of Cancer Cell, Shedding Light On The Role Of Fibrotic Scars In Glioblastoma Treatment Recurrence
Shareholders in 10x Genomics (NASDAQ:TXG) Have Lost 87%, as Stock Drops 7.8% This Past Week
Express News | Stephens & Co. Reiterates Overweight on 10x Genomics, Maintains $30 Price Target
CCORF Maintains 10x Genomics(TXG.US) With Buy Rating, Maintains Target Price $32
10x Genomics Unveils Chromium Xo: A Low-Cost Instrument to Expand Access to High-Performance Single Cell Research
Leerink Partners Initiates 10x Genomics(TXG.US) With Buy Rating, Announces Target Price $35
Buy Rating Affirmed for 10x Genomics on Strong Spatial Business Growth and Market Leadership
Express News | 10X Genomics Inc : Leerink Partners Initiates With Outperform Rating; Price Target $35
CS Genetics Promotes Jay Harger, PhD to Chief Operating Officer, and Mike Stubbington, PhD, to Chief Scientific Officer
Gold Rally Loses Steam As Treasury Yields Stabilize, Dollar Rebounds: 6 Miner Stocks See Declines On Wednesday
10x Genomics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Cisco Posts Upbeat Earnings, Joins Tesla, Ulta Beauty, Robinhood, Dell And Other Big Stocks Moving Higher On Thursday
Navigating 11 Analyst Ratings For 10x Genomics
Express News | 10X Genomics Inc : UBS Cuts Target Price to $25 From $30
Starbucks To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Tuesday
10x Genomics Is Maintained at Overweight by Morgan Stanley
10x Genomics Analyst Ratings
Morgan Stanley Maintains 10x Genomics(TXG.US) With Buy Rating, Cuts Target Price to $46